Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
News
The latest news from Retina UK. Please use the filters to find the articles which interest you.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Vitamin A supplements provides no vision benefit to RP patients
Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).
A round-up of the latest research into inherited retinal conditions - February 2024.
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Retina UK awarded prestigious quality standard
The Royal National Institute of Blind People (RNIB) have awarded Retina UK the Visibly Better Employer quality standard.
New Eye Care Support Pathway wins cross-sector backing
New Eye Care Support Pathway wins cross-sector backing for transforming the way people with care needs and sight loss are helped emotionally and practically.